Physician profile
James E Devlin
NPI 1306954722
$835.78
in general payments reported to CMS, 2019-2025
21 companies · $200 in 2025
The $200 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $416 · 2020: $94.04 · 2021: $22.27 · 2022: $44.45 · 2023: $59.03 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $175 · Food and Beverage: $84.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $175.00 |
| Food and Beverage | $84.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $190.44 | 2019-2025 | Prolia |
| Glaxosmithkline, LLC. | $106.57 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $74.63 | 2019-2020 | |
| Abbvie INC. | $65.38 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $59.03 | 2023 | Eliquis |
| Pfizer INC. | $40.39 | 2019 | |
| Novo Nordisk INC | $39.83 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $35.76 | 2019 | |
| Vapotherm INC | $28.34 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $26.84 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.72 | 2019 | |
| Sanofi Pasteur INC. | $24.27 | 2019-2020 | |
| Lilly USA, LLC | $16.07 | 2019 | |
| Allergan, INC. | $14.52 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.38 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $13.29 | 2020 | |
| Collegium Pharmaceutical, INC. | $12.88 | 2019 | |
| Shire North American Group INC | $12.42 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.23 | 2019 | |
| Amarin Pharma, INC. | $11.54 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $11.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Devlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.